Summary & Overview
HCPCS J2941: Injection, Somatropin, 1 mg
HCPCS Level II code J2941 denotes the administration of somatropin measured in 1 mg units. Somatropin is recombinant human growth hormone used across several pediatric and adult endocrine indications; accurate coding of this drug is important for clinical documentation, inventory management, and payer reimbursement nationally. This publication focuses on national coding and billing context rather than state-specific rules.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical context, typical sites of service, and common billing modifiers associated with injectables. The report summarizes payer coverage patterns and benchmark considerations where available and highlights policy updates affecting coverage determinations and prior authorization practices. Additionally, the publication outlines operational considerations for billing somatropin by unit, documentation elements that support medically necessary use, and related service-line implications for outpatient and ambulatory settings.
This summary provides a concise reference for revenue cycle, clinical teams, and compliance staff seeking to understand how HCPCS Level II code J2941 is used in practice and where to look for payer-specific rules and updates.
Billing Code Overview
HCPCS Level II code J2941 represents an injection of somatropin, dosed per 1 mg units. This code is used to report administration of recombinant human growth hormone for indications requiring somatropin therapy.
Service Type: Injectable medication administration (somatropin)
Typical Site of Service: Outpatient clinics, physician offices, ambulatory care centers, and infusion/ injection suites
Clinical & Coding Specifications
Clinical Context
A pediatric or adult patient with growth hormone deficiency presents to an outpatient specialty clinic or hospital outpatient infusion center for administration of recombinant human growth hormone (somatropin). Typical referral originates from an endocrinologist after confirmatory testing including serum insulin-like growth factor 1 (IGF-1) and stimulation testing, or from an oncologist for growth hormone replacement following cranial irradiation. The patient arrives for a scheduled injection visit or teaching session.
The clinical workflow includes verification of the medication order for J2941 (somatropin, 1 mg), review of the most recent weight and dosing regimen, allergy and adverse reaction check, and assessment for any contraindications (active malignancy, intracranial hypertension, uncontrolled diabetes). For patients or caregivers new to subcutaneous injections, nursing provides injection education and demonstrates proper reconstitution and subcutaneous technique; subsequent doses may be administered by the patient or caregiver at home. For clinic-administered injections, the nurse prepares the dose per manufacturer instructions, documents lot number and expiration, administers the subcutaneous injection (typically thigh, abdomen, or upper arm), observes the patient for immediate adverse reactions, and documents the service in the medical record and medication administration log. Billing uses HCPCS Level II code J2941 per milligram of somatropin dispensed/administrated, with appropriate modifier if required by the payer.
Coding Specifications
| Modifier | Description | When to Use |
|---|